News

Filter

1 to 9 of 37 results

2014 tough year for GlaxoSmithKline, but 4th qtr EPS beats forecasts

2014 tough year for GlaxoSmithKline, but 4th qtr EPS beats forecasts

04-02-2015

UK pharma major GlaxoSmithKline saw its shares rise 2.8% to £14.94 shortly after reporting fourth-quarter…

Core EPsFinancialGlaxoSmithKlinePharmaceuticalViiV Healthcare

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

08-01-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

Experts' comments on GSK floating its HIV business

Experts' comments on GSK floating its HIV business

24-10-2014

The announcement this week by UK pharma giant GlaxoSmithKline that it is mulling a possible initial public…

FinancialGlaxoSmithKlinePharmaceuticalViiV Healthcare

GlaxoSmithKline’s third-qtr results not as bad as expected

GlaxoSmithKline’s third-qtr results not as bad as expected

22-10-2014

UK pharma giant GlaxoSmithKline has reported a downturn in both sales and profits for the third quarter…

FinancialGlaxoSmithKlinePharmaceuticalThomson ReutersUKViiV Healthcare

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

03-09-2014

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq (dolutegravir…

Anti-viralsEuropeGlaxoSmithKlinePharmaceuticalRegulationTriumeqViiV Healthcare

ViiV Healthcare gains FDA approval for HIV drug Triumeq

ViiV Healthcare gains FDA approval for HIV drug Triumeq

23-08-2014

The US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine…

Anti-viralsGlaxoSmithKlinePfizerPharmaceuticalRegulationShionogiTriumeqUSAViiV Healthcare

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

1 to 9 of 37 results

COMPANY SPOTLIGHT

Menarini

Back to top